Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Testosterone: Functions and Regulation01:26

Testosterone: Functions and Regulation

2.6K
The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
2.6K
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.3K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.3K
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

68
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
68
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

233
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
233
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

1.6K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.6K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

288
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
288

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Testosterone Therapy After Radical Prostatectomy: Insights From a Systematic Review and Meta-Analysis.

Andrology·2026
Same author

A comparative evaluation of on-demand phosphodiesterase-5 inhibitor efficacy in erectile dysfunction treatment: a systematic review and network meta-analysis of double-blind, placebo-controlled, randomized trials.

The journal of sexual medicine·2026
Same author

Rethinking hypercortisolism screening in obesity and diabetes: A systematic review and meta-analysis.

Metabolism: clinical and experimental·2026
Same author

Correction: Penile prosthesis implantation: a systematic review of intraoperative and postoperative complications.

International journal of impotence research·2026
Same author

EAU Guidelines on Sexual and Reproductive Health: A Summary of the 2026 Recommendations for Measurement and Biochemical Confirmation of Hypogonadism.

European urology focus·2026
Same author

Emerging Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Male Sexual Hormones and Behaviors: Systematic Review and Meta-Analysis.

Andrology·2026

Related Experiment Video

Updated: Mar 2, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Testosterone Replacement Therapy: Long-Term Safety and Efficacy.

Giovanni Corona1, Alessandra Sforza1, Mario Maggi2

  • 1Endocrinology Unit, Medical Department, Azienda USL, Maggiore-Bellaria Hospital, Bologna, Italy.

The World Journal of Men'S Health
|May 13, 2017
PubMed
Summary
This summary is machine-generated.

Testosterone therapy (TTh) effectively treats sexual dysfunction in age-related hypogonadism (HG), including late-onset hypogonadism (LOH). Properly diagnosed HG and correct TTh show no increased cardiovascular or prostate risks.

Keywords:
Erectile dysfunctionHypogonadismProstateSafetyTestosterone

More Related Videos

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.6K
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

4.0K

Related Experiment Videos

Last Updated: Mar 2, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.6K
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

4.0K

Area of Science:

  • Endocrinology
  • Men's Health
  • Gerontology

Background:

  • Distinguishing true hypogonadism (HG) from late-onset hypogonadism (LOH) is crucial.
  • LOH is often linked to comorbidities and may not require testosterone therapy (TTh).
  • Cardiovascular safety concerns have increased skepticism regarding TTh.

Purpose of the Study:

  • To review evidence on TTh efficacy in non-organic HG.
  • To assess the long-term safety of TTh.
  • To address cardiovascular safety concerns associated with TTh.

Main Methods:

  • Literature review of available evidence.
  • Analysis of studies on TTh efficacy and safety.
  • Evaluation of cardiovascular safety data and methodological flaws in trials.

Main Results:

  • Sexual symptoms are specific correlates of testosterone deficiency.
  • TTh improves sexual function regardless of the cause of HG, supporting the existence of LOH.
  • TTh positively impacts body composition and insulin sensitivity, potentially counterbalancing reduced efficacy in erectile dysfunction due to metabolic issues.
  • Methodological flaws in trials limit the validity of cardiovascular safety concerns.
  • Properly diagnosed HG and correct TTh show no documented cardiovascular or prostate risks.

Conclusions:

  • Testosterone therapy is effective for sexual dysfunction in hypogonadism, including late-onset hypogonadism.
  • Long-term testosterone therapy is safe when hypogonadism is properly diagnosed and treatment is correctly administered.
  • Evidence does not support increased cardiovascular or prostate risks with appropriate testosterone therapy.